|
|
|
|
| 20-minute capacity and capabilities quick-looks, 20+ brand new CDMO presenters to evaluate for best-fit this quarter – and a (virtual) commitment of less than 20 percent of your day? We’re confident you don’t need 20/20 vision to see the value in this! Join us for Outsourced Pharma’s July Partner Week – including sessions in Small Molecule API/HPAPI, Small Molecule Finished Dosage Form, ADC, Analytical Services, and Fill/Finish among others. Registration, on-demand access, and interactive Q&A are free. |
|
|
|
5 Must-Haves In A Contract Packaging Partner | Article | By Yves Massicotte, Ropack Pharma Solutions | A partner should function as an extension of the pharma’s organization, so careful consideration should be devoted to initiating this relationship. |
|
|
|
Customized Release Through Dispersed Dosage Formats | Article | By Nathan Dormer, Ph.D., Adare Pharma Solutions | Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Dileep Boinipally has extensive experience in formulation, manufacturing process development, and regulatory strategy. He’s adept at explaining all that, but Chief Editor Louis Garguilo got him to focus for readers on the ins-and-outs of the practice of early formulation development. | |
|
|
Should Your CDMO Run 'Technical' Batches? | By Outsourced Pharma Live | Our panel pitches in on the need for "extra" technical, tox or engineering batches to further ensure manufacturing success, and considering tight budgets at biotechs. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
'Ultra High' Potency Development And Manufacture | Case Study | Cambrex | A biotech with limited experience in the development of high-potency compounds sought to develop a process for producing a highly potent API used to treat an unmet oncology need. |
|
|
|
|
Solutions For Accelerated Pharmaceutical Development | Article | By David K. Lyon, Ph.D. and Conrad Roten, Ph.D., Lonza | Discover an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability. |
|
|
|
|
|
|
Predictive Modeling Services | Lonza | Early identification of potential absorption risks is critical for rapid and efficient drug development. PBPK modeling services are designed to de-risk your drug development program. |
|
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
